Treatment outcome of switching from ranibizumab to aflibercept in patients with central retinal vein occlusion

被引：0
|
作者：
Konidaris, V.
Gorgoli, K.
Burgula, S.
Deane, J.
Banerjee, S.
Empeslidis, T.
机构：
来源：
ACTA OPHTHALMOLOGICA | 2016年 / 94卷
关键词：
D O I：
10.1111/j.1755-3768.2016.0316
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Clinical Outcome after Switching Therapy from Ranibizumab and/or Bevacizumab to Aflibercept in Central Retinal Vein Occlusion
    Pfau, Maximilian
    Fassnacht-Riederle, Heidi
    Becker, Matthias D.
    Graf, Nicole
    Michels, Stephan
    OPHTHALMIC RESEARCH, 2015, 54 (03) : 150 - 156
  • [2] Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab
    Vasileios Konidaris
    Zahra Al-Hubeshy
    Konstantinos T. Tsaousis
    Konstantina Gorgoli
    Somnath Banerjee
    Theodoros Empeslidis
    International Ophthalmology, 2018, 38 : 207 - 213
  • [3] Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab
    Konidaris, Vasileios
    Al-Hubeshy, Zahra
    Tsaousis, Konstantinos T.
    Gorgoli, Konstantina
    Banerjee, Somnath
    Empeslidis, Theodoros
    INTERNATIONAL OPHTHALMOLOGY, 2018, 38 (01) : 207 - 213
  • [4] Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in Central Retinal Vein Occlusion (CRVO): 1 year results
    Pfau, Maximilian
    Fassnacht-Riederle, Heidi
    Becker, Matthias
    Michels, Stephan
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [5] Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the USA
    D Călugăru
    M Călugăru
    Eye, 2015, 29 : 1113 - 1113
  • [6] Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab
    Papakostas, T. D.
    Lim, L.
    van Zyl, T.
    Miller, J. B.
    Modjtahedi, B. S.
    Andreoli, C. M.
    Wu, D.
    Young, L. H.
    Kim, I. K.
    Vavvas, D. G.
    Esmaili, D. D.
    Husain, D.
    Eliott, D.
    Kim, L. A.
    EYE, 2016, 30 (01) : 79 - 84
  • [7] Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab
    T D Papakostas
    L Lim
    T van Zyl
    J B Miller
    B S Modjtahedi
    C M Andreoli
    D Wu
    L H Young
    I K Kim
    D G Vavvas
    D D Esmaili
    D Husain
    D Eliott
    L A Kim
    Eye, 2016, 30 : 79 - 84
  • [8] Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the USA
    A J Lotery
    S Regnier
    Eye, 2015, 29 : 380 - 387
  • [9] Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the USA
    Lotery, A. J.
    Regnier, S.
    EYE, 2015, 29 (03) : 380 - 387
  • [10] Extended Injection Intervals after Switching from Ranibizumab to Aflibercept in Macular Edema due to Central Retinal Vein Occlusion
    Nghiem-Buffet, Sylvia
    Glacet-Bernard, Agnes
    Addou-Regnard, Manar
    Souied, Eric H.
    Cohen, Salomon Y.
    Giocanti-Auregan, Audrey
    JOURNAL OF OPHTHALMOLOGY, 2018, 2018
12345